Back to search results

Observational Study for Breast Cancer After Chemotherapy or Endocrine Therapy

This observational study is for breast cancer patients who have residual (remaining) cancer after completing chemotherapy or endocrine therapy. The study aims to collect blood and leftover surgical tissue from you to create patient-derived xenografts (PDX) and organoids. These are models grown in the lab that help researchers understand your specific cancer better. The goal is to find new ways to treat breast cancer, especially for patients who still have cancer after initial treatments. The study will follow the progress of these lab models for up to 20 years to see how they develop. We are looking for about 999 participants, but the current recruitment status is unclear.

Study design
This is an observational study with a planned enrollment of 999 participants. It is not a treatment study but focuses on collecting samples for future research.
What's involved
You would provide blood samples and leftover surgical tissue from your breast cancer surgery. The study does not specify additional visits or procedures beyond these collections.
Compensation
Not stated in the trial record.
Follow-up
The primary endpoint, generating PDX and organoids, will be measured for up to 12 months until death or a maximum of 20 years post-registration.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT04703244

Development of Patient Derived Xenografts (PDX) in Patients With Breast Cancer

Recruiting
Not specifiedAges 18+Observational
Mayo Clinic
~999 participants
Updated 2026-03-03 on ClinicalTrials.gov
What's tested:chemotherapy or endocrine therapy for breast cancer

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Generate patient derived xenografts (PDX) and organoids from breast cancer patients with residual disease after neoadjuvant therapy
Measured over Up to 12 months until death or a maximum of 20 years post registration

Conditions

Breast Cancer
Residual

Explore related trials

Breast Carcinoma

Where it's being run

1 sites across 1 states
Minnesota1

Study leadership

  • Judy C. Boughey, M.D. · PRINCIPAL_INVESTIGATOR · Mayo Clinic
  • Matthew P. Goetz, M.D. · PRINCIPAL_INVESTIGATOR · Mayo Clinic

Who to contact

Clinical Trials Referral Office
[email protected]
855-776-0015
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Age ≥18 years.
Diagnosis of invasive breast cancer treated with neoadjuvant systemic therapy.
Surgically resectable disease following neoadjuvant systemic treatment.
At least one of the following must be true:
Received at least 2 weeks of neoadjuvant endocrine therapy
Received at least 2 months of neoadjuvant chemotherapy with suggestion of residual disease on imaging
Began neoadjuvant chemotherapy or endocrine therapy but discontinued due to evidence of progressive disease by MRI, ultrasound, or physical examination
Provide written informed consent.
Willing to return to enrolling institution for breast cancer surgery.
Willingness to provide mandatory blood specimens for future research on breast cancer at Mayo Clinic.
Willingness to provide mandatory tissue specimens for future research on breast cancer at Mayo Clinic.
Willingness to provide mandatory tissue specimens for the generation of PDX and organoids to be used future research on breast cancer at Mayo Clinic.

Exclusion

Ineligible for surgery.
History of prior malignancy \<3 years prior to registration. Exceptions for non-melanoma skin cancer, papillary thyroid cancer, non-invasive cancer (e.g., carcinoma in situ of the cervix).

What this trial measures

  • Generate patient derived xenografts (PDX) and organoids from breast cancer patients with residual disease after neoadjuvant therapyUp to 12 months until death or a maximum of 20 years post registration